News

Cerillo Unveils Co-Culture Duet System for Real-Time Observation of Microbial Interaction Studies

Cerillo, a biotechnology company at the forefront of developing advanced research platforms for the study of the microbiome, hosted demonstrations of the company’s new co-culture duet system at ASM Microbe 2023.

Cerillo’s co-culture system will enable researchers to observe and study individual microbial populations in real time and measure the growth of one microbial population alongside other populations. The system’s porous barrier can physically isolate populations while maintaining fluidic contact, allowing researchers to mimic natural microbiome conditions and study the interactions between microorganisms.

The co-culture system is also scalable since it can be read in multiple microplate readers, each wirelessly connected to the company’s analytic software. This wireless feature can also help researchers capture and analyze growth data as it happens, enabling them to monitor and adjust their experiments in real time.

Until now, researchers faced the constraints of limited off-the-shelf co-culture options, demanding substantial investments of time and resources in developing custom systems for their studies. “Cerillo is dedicated to liberating microbiome researchers from the constraints of conventional laboratory technologies,” says Eric Mayton, CEO of Cerillo. “Our new co-culture system is a game-changer since it is the world’s first scalable, user-friendly, and cost-effective co-culture system.”

Applications

Cerillo’s co-culture system enables researchers to:

  • Mimic natural conditions: Microorganisms in the environment often exist in complex communities, where they interact with each other. Cerillo’s co-culture system allows researchers to mimic these natural conditions and study the interactions between microorganisms.
  • Improve understanding of microbial interactions: Cerillo’s co-culture system can provide insight into how microorganisms interact with each other. For example, one microorganism may produce a compound that benefits another microorganism, or one microorganism may inhibit the growth of another. These interactions can be difficult to study in isolation.
  • Identify novel compounds: Our system can also be used to identify novel compounds that are produced by microorganisms. For example, one microorganism may produce a compound that is only active in the presence of another microorganism.
  • Develop new therapies: Cerillo’s co-culture system can be used to screen for potential therapeutics by testing the ability of a compound to inhibit the growth of a pathogenic microorganism in the presence of a beneficial microorganism.

Features and Benefits

  • multiplexed plate accommodates 18 duets
  • physically accessible wells enable population sampling during and after experiments
  • compatible with other automation systems, giving you the freedom and flexibility to run additional assays on different platforms
  • effective for quick proofs-of-concept, and also preconfigured for higher-throughput work, making it suitable for a wide range of experiment types
  • scalable, enabling high-throughput experiments for faster results and comprehensive data analysis
  • small and robust to harsh conditions of incubators and anaerobic chambers
  • easily access your data without physical contact with your plate reader and manual memory cards

Learn more.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation